Bone Biologics Co. (NASDAQ:BBLG) Short Interest Update

Bone Biologics Co. (NASDAQ:BBLGGet Free Report) saw a significant decline in short interest in the month of August. As of August 31st, there was short interest totalling 7,600 shares, a decline of 29.6% from the August 15th total of 10,800 shares. Approximately 0.3% of the shares of the company are short sold. Based on an average trading volume of 401,000 shares, the short-interest ratio is presently 0.0 days.

Bone Biologics Price Performance

NASDAQ:BBLG opened at $0.72 on Friday. The company has a market cap of $2.25 million, a PE ratio of -0.08 and a beta of 0.21. Bone Biologics has a 52 week low of $0.57 and a 52 week high of $41.70.

Bone Biologics (NASDAQ:BBLGGet Free Report) last issued its earnings results on Monday, August 14th. The company reported ($1.69) earnings per share for the quarter, missing the consensus estimate of ($1.50) by ($0.19). Equities research analysts anticipate that Bone Biologics will post -8.15 EPS for the current year.

Bone Biologics Company Profile

(Get Free Report)

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L2-S1.

Read More

Receive News & Ratings for Bone Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bone Biologics and related companies with's FREE daily email newsletter.